Skip to main content

Table 4 Number of hypermethylated markers in recurrent lesions

From: Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence

 

Sensitivity (%)

Specificity (%)

Accuracy (%)

(95%CI)

(95%CI)

(95%CI)

a) FHIT, MLH1, ATM

   

≥1

61.29 (43.82-76.27)

93.61 (82.84-97.81)

80.76 (72.02-89.52)

≥2

22.58 (11.40-39.81)

100 (92.44-100)

69.23 (58.99-79.47)

≥3

6.45 (1.79-20.72)

100 (92.44-100)

62.82 (52.09-73.55)

b) FHIT, MLH1, ATM, TP73, BRCA1

   

≥1

70.96 (53.41-83.90)

85.11 (72.31-92.59)

79.49 (70.53-88.45)

≥2

38.71 (23.73-56.18)

95.74 (85.75-98.83)

73.08 (63.24-82.92)

≥3

16.13 (7.09-32.63)

100 (92.44-100)

66.66 (56.21-77.13)

≥4

6.45 (1.79-20.72)

100 (92.44-100)

62.82 (52.09-73.55)

≥5

3.22 (0.57-16.19)

100 (92.44-100)

61.53 (50.74-72.34)

c) FHIT, MLH1

   

≥1

58.06 (40.77-73.58)

95.74 (85.75-98.83)

80.77 (72.02-89.52)

≥2

9.68 (3.35-24.90)

100 (92.44-100)

64.10 (53.45-74.75)

  1. Sensitivity, R patients who were correctly identified by the hypermethylated profile; Specificity, NR patients who were correctly identified by the hypermethylated profile; Accuracy, R patients, correctly identified by the hypermethylated profile, and NR patients, correctly identified by the hypermethylated profile, divided by the total series; 95% CI, 95% confidence intervals.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us